A number of MET inhibitors, such as tivantinib, tepotinib, and capmatinib, have been evaluated in advanced HCC patients with especially high MET expression and previously treated with sorafenib [169,170,171]. The gene discussed is MET; the disease is hepatocellular carcinoma.